↓ Skip to main content

Simvastatin treatment does not affect serum Vitamin D concentrations in patients with dyslipidemia: A randomized double-blind placebo-controlled cross-over trial

Overview of attention for article published in International Journal of Preventive Medicine, January 2016
Altmetric Badge

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
36 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Simvastatin treatment does not affect serum Vitamin D concentrations in patients with dyslipidemia: A randomized double-blind placebo-controlled cross-over trial
Published in
International Journal of Preventive Medicine, January 2016
DOI 10.4103/2008-7802.183652
Pubmed ID
Authors

Mohsen Mazidi, Haleh Rokni, AmirHossein Sahebkar, Akram Mohammadi, Majid Ghayour-Mobarhan, GordonA Ferns

Abstract

Hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins) are antihyperlipidemic drugs with an established efficacy in stabilizing atherosclerotic plaques and preventing atherogenesis and reducing cardiovascular events. The purpose of this study was to determine the effect of simvastatin on serum Vitamin D status in dyslipidemic patients as Vitamin D status has an impact on monocyte/macrophage function and may also contribute to cardiovascular risk. Selected individuals (n = 102) were treated with simvastatin (40 mg/day), or matching placebo in a randomized, double-blind, placebo-controlled, crossover trial. Each treatment period (with simvastatin or placebo) lasted for 30 days and was separated by a 2-week washout phase. Serum Vitamin D concentration was assessed pre- and post-treatment. Seventy-seven completed the trial, noncompliance with the study protocol and drug intolerance or relocation were the causes for drop-out. No significant carry-over effect was observed for the assessed parameters. There was a reduction in the serum levels of low-density lipoprotein cholesterol (P < 0.001), total cholesterol (P < 0.001), and triglycerides (P < 0.05). Nevertheless, simvastatin therapy did not significantly affect serum level of high-density lipoprotein cholesterol and Vitamin D level (P > 0.05). Short-term treatment with simvastatin (40 mg/day) does not have a significant affect on serum levels of Vitamin D.

Mendeley readers

The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Netherlands 1 3%
Unknown 35 97%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 5 14%
Student > Master 4 11%
Student > Doctoral Student 3 8%
Researcher 3 8%
Student > Bachelor 2 6%
Other 6 17%
Unknown 13 36%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 4 11%
Social Sciences 3 8%
Biochemistry, Genetics and Molecular Biology 2 6%
Business, Management and Accounting 2 6%
Agricultural and Biological Sciences 2 6%
Other 6 17%
Unknown 17 47%